Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) EPS (Basic): 2009-2025

Historic EPS (Basic) for Northwest Biotherapeutics (NWBO) over the last 17 years, with Sep 2025 value amounting to -$0.02.

  • Northwest Biotherapeutics' EPS (Basic) changed negligibly% to -$0.02 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.06, marking a year-over-year increase of 14.29%. This contributed to the annual value of -$0.07 for FY2024, which is 16.67% down from last year.
  • Per Northwest Biotherapeutics' latest filing, its EPS (Basic) stood at -$0.02 for Q3 2025, which was down 100.00% from -$0.01 recorded in Q2 2025.
  • Over the past 5 years, Northwest Biotherapeutics' EPS (Basic) peaked at $0.16 during Q4 2021, and registered a low of -$0.03 during Q3 2022.
  • For the 3-year period, Northwest Biotherapeutics' EPS (Basic) averaged around -$0.02, with its median value being -$0.02 (2025).
  • Data for Northwest Biotherapeutics' EPS (Basic) shows a peak YoY increase of 143.24% (in 2021) and a maximum YoY decrease of 220.95% (in 2021) over the last 5 years.
  • Over the past 5 years, Northwest Biotherapeutics' EPS (Basic) (Quarterly) stood at $0.16 in 2021, then tumbled by 112.50% to -$0.02 in 2022, then surged by 50.00% to -$0.01 in 2023, then slumped by 100.00% to -$0.02 in 2024, then remained steady at -$0.02 in 2025.
  • Its EPS (Basic) was -$0.02 in Q3 2025, compared to -$0.01 in Q2 2025 and -$0.01 in Q1 2025.